NASDAQ:VLRX - Valeritas Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.37 0.00 (0.00 %) (As of 12/13/2018 01:08 AM ET)Previous Close$0.3732Today's Range$0.35 - $0.3952-Week Range$0.31 - $4.72Volume1.75 million shsAverage Volume775,313 shsMarket Capitalization$8.11 millionP/E Ratio-0.04Dividend YieldN/ABeta2.31 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery. In addition, its products include V-Go Prefill, which is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go Link that is in the early stages of development for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors in the United States. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey. Receive VLRX News and Ratings via Email Sign-up to receive the latest news and ratings for VLRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VLRX Previous Symbol CUSIPN/A Webwww.valeritas.com Phone908-927-9920 Debt Debt-to-Equity Ratio13.66 Current Ratio3.00 Quick Ratio2.47 Price-To-Earnings Trailing P/E Ratio-0.04 Forward P/E Ratio-0.28 P/E GrowthN/A Sales & Book Value Annual Sales$20.25 million Price / Sales0.46 Cash FlowN/A Price / Cash FlowN/A Book Value($0.59) per share Price / Book-0.63 Profitability EPS (Most Recent Fiscal Year)($8.29) Net Income$-49,300,000.00 Net Margins-193.79% Return on Equity-1,768.69% Return on Assets-102.96% Miscellaneous Employees103 Outstanding Shares24,950,000Market Cap$8.11 million OptionableNot Optionable Valeritas (NASDAQ:VLRX) Frequently Asked Questions What is Valeritas' stock symbol? Valeritas trades on the NASDAQ under the ticker symbol "VLRX." How were Valeritas' earnings last quarter? Valeritas Holdings Inc (NASDAQ:VLRX) issued its quarterly earnings results on Friday, November, 9th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.07. The company had revenue of $6.93 million for the quarter. Valeritas had a negative return on equity of 1,768.69% and a negative net margin of 193.79%. View Valeritas' Earnings History. When is Valeritas' next earnings date? Valeritas is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Valeritas. What guidance has Valeritas issued on next quarter's earnings? Valeritas updated its FY 2018 earnings guidance on Friday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $26-26.5 million, compared to the consensus revenue estimate of $26.85 million. What price target have analysts set for VLRX? 4 brokers have issued 1-year price objectives for Valeritas' shares. Their forecasts range from $1.00 to $3.50. On average, they expect Valeritas' stock price to reach $2.1667 in the next twelve months. This suggests a possible upside of 485.6% from the stock's current price. View Analyst Price Targets for Valeritas. What is the consensus analysts' recommendation for Valeritas? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valeritas in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Valeritas. Has Valeritas been receiving favorable news coverage? Media headlines about VLRX stock have been trending very positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Valeritas earned a coverage optimism score of 3.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. Are investors shorting Valeritas? Valeritas saw a drop in short interest in November. As of November 30th, there was short interest totalling 1,760,954 shares, a drop of 48.8% from the November 15th total of 3,439,674 shares. Based on an average daily volume of 3,619,793 shares, the short-interest ratio is presently 0.5 days. Approximately 2.3% of the shares of the company are sold short. View Valeritas' Current Options Chain. Who are some of Valeritas' key competitors? Some companies that are related to Valeritas include Interpace Diagnostics Group (IDXG), Lianluo Smart (LLIT), PAVmed (PAVM), Titan Medical (TMDI), Hancock Jaffe Laboratories (HJLI), Dynatronics (DYNT), DarioHealth (DRIO), Invivo Therapeutics (NVIV), Neovasc (NVCN), CELLECT BIOTECH/S (APOP), Biostage (BSTG), Alliqua Biomedical (ALQA), Presbia (LENS), Avinger (AVGR) and Atossa Genetics (ATOS). Who are Valeritas' key executives? Valeritas' management team includes the folowing people: Mr. John E. Timberlake, Pres, CEO & Director (Age 53)Mr. Erick J. Lucera CPA, CFA, Chief Financial Officer (Age 50)Mr. Geoffrey H. Jenkins, Exec. VP of Manufacturing, Operations and R&D (Age 66)Dr. Matthew H. Nguyen, Chief Commercial Officer (Age 48)Mr. Scott A. Huie, VP of Regulatory Affairs/Quality Assurance and Compliance When did Valeritas IPO? (VLRX) raised $60 million in an initial public offering (IPO) on Thursday, March 23rd 2017. The company issued 6,000,000 shares at a price of $9.00-$11.00 per share. Cowen and Company and Wedbush PacGrow acted as the underwriters for the IPO and Roth Capital Partners and B. Riley & Co. were co-managers. Who are Valeritas' major shareholders? Valeritas' stock is owned by a number of of institutional and retail investors. Top institutional investors include C WorldWide Group Holding A S (1.09%) and Renaissance Technologies LLC (0.66%). Company insiders that own Valeritas stock include Armistice Capital Master Fund, Brian K Roberts, Capital Royalty LP, Erick Lucera, Geoffrey Jenkins, John Edward Timberlake, Joseph M Mandato, Matt Nguyen, Matt Nguygn and Peter Devlin. View Institutional Ownership Trends for Valeritas. Which institutional investors are selling Valeritas stock? VLRX stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S. View Insider Buying and Selling for Valeritas. Which institutional investors are buying Valeritas stock? VLRX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Valeritas stock in the last two years include Armistice Capital Master Fund, Brian K Roberts, Capital Royalty LP, Erick Lucera, Geoffrey Jenkins, John Edward Timberlake, Joseph M Mandato, Matt Nguyen, Matt Nguygn and Peter Devlin. View Insider Buying and Selling for Valeritas. How do I buy shares of Valeritas? Shares of VLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Valeritas' stock price today? One share of VLRX stock can currently be purchased for approximately $0.37. How big of a company is Valeritas? Valeritas has a market capitalization of $8.11 million and generates $20.25 million in revenue each year. The company earns $-49,300,000.00 in net income (profit) each year or ($8.29) on an earnings per share basis. Valeritas employs 103 workers across the globe. What is Valeritas' official website? The official website for Valeritas is http://www.valeritas.com. How can I contact Valeritas? Valeritas' mailing address is 750 ROUTE 202 SOUTH SUITE 600, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-927-9920 or via email at [email protected] MarketBeat Community Rating for Valeritas (NASDAQ VLRX)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 150 (Vote Outperform)Underperform Votes: 87 (Vote Underperform)Total Votes: 237MarketBeat's community ratings are surveys of what our community members think about Valeritas and other stocks. Vote "Outperform" if you believe VLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VLRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?